Our Expert Faculty member, Dr Gil Y Melmed (Cedars-Sinai Medical Center, Los Angeles, CA, US), spoke with touchIMMUNOLOGY around the rationale for targeting IL-23 in the treatment of Crohn’s disease and the clinical development of risankizumab.
- What are the limitations of current biologic drugs in the treatment of patients with Crohn’s disease? (0:10)
- What is the rationale for targeting IL-23 in Crohn’s disease? (1:03)
- Could you give us a brief overview of the clinical development of risankizumab? (2:55)
Disclosures: Gil Y Melmed has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Share this Video
Related Videos In Inflammatory Bowel Disease
Marc Ferratnte, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Marc Ferrante, UEG 2021: Risankizumab as a Maintenance Therapy for Crohn’s Disease
Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) kindly took the time to speak with touchIMMUNOLOGY about the 52-week results from the phase 3 FORTIFY study investigating the efficacy and safety of risankizumab as a maintenance treatment in patients with Crohn’s disease. His presentation entitled ‘EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS […]
Marc Ferrante, UEG 2021: Unmet Needs in Managing Crohn’s Disease
It was a pleasure to discuss with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) the current unmet needs in the treatment of patients with Crohn’s disease. Disclosures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!